Butrans Patch, Extended Release
Product Images NDC 59011-751

31 FDA label images from Knoa Pharma Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 31 technical images submitted to the FDA as part of the official labeling for Butrans (NDC 59011-751). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Knoa Pharma Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Table 1 (Butrans 01)

Table 1 (Butrans 01)
A dose recommendation chart for Butrans (buprenorphine) transdermal patches. It relates previous opioid analgesic daily dose in oral morphine equivalents to the recommended Butrans starting dose, indicating 5 mcg/hour for doses ≤30 mg and 10 mcg/hour for doses between 30-80 mg.*
FDA Label Image

Chemical Structure (Butrans 02)

Chemical Structure (Butrans 02)
Chemical structure of buprenorphine, the active ingredient in Butrans. The diagram shows the molecule's detailed arrangement of carbon, hydrogen, oxygen, and nitrogen atoms, illustrating its complex polycyclic structure with various functional groups.*
FDA Label Image

Fig 1 (Butrans 03)

Fig 1 (Butrans 03)
An instructional diagram showing the cross-sectional layers of the Butrans buprenorphine transdermal patch, extended release. The layers labeled include the backing layer, overlapping adhesive film, separating layer, drug/polymer adhesive matrix, and peel-off release liner.*
FDA Label Image

Fig 2 (Butrans 04)

Fig 2 (Butrans 04)
A line graph depicting the concentration of buprenorphine (pg/mL) over time in days following administration of Butrans 10 mcg/hour applied every 7 days for three cycles (N=36). The plot shows three peaks of concentration corresponding to each application, with a sharp decline after removal of Butrans on day 21.*
FDA Label Image

Fig 3 (Butrans 05)

Fig 3 (Butrans 05)
A line graph comparing the percentage of patients improved versus the percent of reduction/improvement in pain. It shows two lines: one for placebo and one for Butrans 10/20 micrograms per hour, with Butrans data consistently showing a higher percentage of patient improvement across various pain reduction thresholds.*
FDA Label Image

Fig 4 (Butrans 06)

Fig 4 (Butrans 06)
Line graph depicting the percentage of patients improved versus the percent reduction/improvement in pain for Butrans extended-release transdermal patches at 5 ug/h and 20 ug/h strengths. The graph displays two curves, one for Butrans 5 and another for Butrans 20, showing higher patient improvement percentages at lower pain reduction thresholds for the 20 ug/h strength.*
FDA Label Image

Fig A (Butrans 07)

Fig A (Butrans 07)
An instructional diagram showing four placement sites for the Butrans (buprenorphine) transdermal patch on the human body: upper outer arm, upper chest, upper back, and side of the torso below the armpit.*
FDA Label Image

Fig B (Butrans 08)

Fig B (Butrans 08)
An illustration showing the upper back and shoulder area of a person with two rectangular patches placed side-by-side on the left upper back. This diagram likely demonstrates the application site for the Butrans buprenorphine extended-release transdermal patch.*
FDA Label Image

Fig C (Butrans 09)

Fig C (Butrans 09)
An instructional line drawing showing a person using scissors to cut or open a patch from the chest area. The illustration likely corresponds to directions for handling or applying a transdermal patch like Butrans (buprenorphine) extended-release patch.*
FDA Label Image

Fig D (Butrans 10)

Fig D (Butrans 10)
An instructional illustration showing a person using scissors to cut open a pouch or package, likely for a Butrans buprenorphine transdermal patch. The hands demonstrate the opening method by cutting along one edge of the sealed packet.*
FDA Label Image

Fig E (Butrans 11)

Fig E (Butrans 11)
An instructional illustration showing a transdermal Butrans patch with its foil backing partially peeled back using a foil handle. The image highlights the patch placement on the foil backing and the handle used to remove it, demonstrating product handling for application.*
FDA Label Image

Fig F (Butrans 12)

Fig F (Butrans 12)
An instructional line drawing showing a person peeling a protective liner off a transdermal patch, demonstrating the proper handling for applying a transdermal drug patch. The image focuses on hand movements without showing the product's branding or labeling.*
FDA Label Image

Fig G (Butrans 13)

Fig G (Butrans 13)
An instructional illustration showing a person applying a Butrans transdermal patch to the upper chest area. The image highlights the appropriate placement site for the extended-release buprenorphine patch.*
FDA Label Image

Fig H (Butrans 14)

Fig H (Butrans 14)
An instructional black-and-white line drawing showing a person applying a Butrans buprenorphine transdermal patch to the upper chest area. The person is using one hand to peel the patch from its backing while the other hand holds the patch in place on the skin.*
FDA Label Image

Fig I (Butrans 15)

Fig I (Butrans 15)
An instructional illustration showing the correct placement of the Butrans buprenorphine extended-release transdermal patch on the upper chest area of a person. The image depicts a hand applying the patch to the skin near the shoulder.*
FDA Label Image

Fig J (Butrans 16)

Fig J (Butrans 16)
An instructional illustration showing hands opening a package labeled 'STEP 1'. It depicts the initial step in the use or application process of a product, likely for preparing the transdermal patch for use.*
FDA Label Image

Fig K (Butrans 17)

Fig K (Butrans 17)
An instructional illustration showing a person peeling the protective liner off a Butrans buprenorphine transdermal patch before applying it to the skin. The drawing highlights hand positioning during patch application.*
FDA Label Image

Fig L (Butrans 18)

Fig L (Butrans 18)
An instructional illustration showing two hands peeling a protective liner from a square-shaped transdermal patch. The visible text on the liner includes 'STEP 3' with directions to remove the release liner and apply the patch to the skin. This likely depicts how to properly use the Butrans buprenorphine extended-release transdermal patch.*
FDA Label Image

Fig M (Butrans 19)

Fig M (Butrans 19)
An instructional illustration depicting a person's hands peeling back a protective layer from a transdermal patch to prepare it for application on the skin.*
FDA Label Image

Fig N (Butrans 20)

Fig N (Butrans 20)
An instructional illustration showing a hand discarding a square object into a trash can with an open lid, likely representing disposal instructions for a used butrans buprenorphine transdermal patch.*
FDA Label Image

Fig O (Butrans 21)

Fig O (Butrans 21)
An instructional illustration showing a hand placing a used adhesive patch into a round, lidded disposal container. The image likely demonstrates safe disposal of the Butrans transdermal patch to prevent accidental exposure.*
FDA Label Image

Principal Display Panel (10 mcg Pouch Label)

Principal Display Panel (10 mcg Pouch Label)
Butrans 10 mcg/hour (buprenorphine) transdermal system label. It indicates the product is an extended-release patch for systemic delivery of 10 mcg per hour of buprenorphine. The label includes warnings about serious breathing problems, dosage instructions, storage conditions, manufacturer details (Knoa Pharma LLC), and that it is Rx only. The label is from a foil pouch containing one patch.*
FDA Label Image

Principal Display Panel (10 mcg Pouch Carton)

Principal Display Panel (10 mcg Pouch Carton)
Butrans 10 mcg/hour (buprenorphine) Transdermal System packaging label. The label indicates a transdermal patch providing systemic delivery of 10 mcg per hour of buprenorphine for seven days. The box contains 4 transdermal systems with disposal units. Labeler is Knoa Pharma LLC. Additional warnings and usage instructions are present, along with a section for a pharmacy label.*
FDA Label Image

Principal Display Panel (15 mcg Pouch Label)

Principal Display Panel (15 mcg Pouch Label)
Label of Butrans 15 mcg/hour transdermal patch containing buprenorphine. The label includes usage warnings, dosage instructions, storage conditions, and manufacturer details. It highlights the systemic delivery strength, cautions against using for certain types of pain, and notes it is for prescription use only. The labeler is Knoa Pharma LLC, with manufacturing by LTS Lohmann Therapy Systems Corp.*
FDA Label Image

Principal Display Panel (15 mcg Pouch Carton)

Principal Display Panel (15 mcg Pouch Carton)
Carton packaging label for Butrans 15 mcg/hour (buprenorphine) Transdermal System by Knoa Pharma LLC. The label indicates a box containing 4 transdermal systems and disposal units for sustained delivery of 15 mcg per hour of buprenorphine. Prominent warnings and Rx-only status are included, along with areas marked for pharmacy label and bar code placement.*
FDA Label Image

Principal Display Panel (20 mcg Pouch Label)

Principal Display Panel (20 mcg Pouch Label)
Label for Butrans 20 mcg/hour buprenorphine transdermal system patch. The label highlights the extended-release transdermal patch delivering 20 micrograms per hour of buprenorphine for seven days. It includes warnings about serious breathing problems, storage instructions, and manufacturer details: Knoa Pharma LLC and LTS Lohmann Therapy Systems Corp. The patch is intended for prescription use only.*
FDA Label Image

Principal Display Panel (20 mcg Pouch Carton)

Principal Display Panel (20 mcg Pouch Carton)
Butrans 20 mcg/hour (buprenorphine) Transdermal System box packaging label. The label includes dosage strength, dosage form as transdermal patch, and contains 4 transdermal systems per package. It also features boxed warnings, usage instructions, and a space for pharmacy labeling. The product is labeled for prescription use only and manufactured by Knoa Pharma LLC.*
FDA Label Image

Principal Display Panel (5 mcg Pouch Label)

Principal Display Panel (5 mcg Pouch Label)
Butrans 5 mcg/hour (buprenorphine) Transdermal System packaging label showing a systemic delivery of 5 mcg per hour of buprenorphine for seven days. Label includes warnings about serious breathing problems and usage restrictions, storage instructions, distributor Knoa Pharma LLC, and manufacturer LTS Lohmann Therapy Systems Corp. The label also notes it is Rx only and contains a barcode.*
FDA Label Image

Principal Display Panel (5 mcg Pouch Carton)

Principal Display Panel (5 mcg Pouch Carton)
Butrans 5 mcg/hour (buprenorphine) Transdermal System packaging label. The label indicates a transdermal patch with systemic delivery of 5 micrograms per hour of buprenorphine for seven days. The package contains 4 transdermal systems, labeled for prescription use only. The labeler is Knoa Pharma LLC. The label features areas marked as 'No Varnish Area' and space for affixing a pharmacy label and barcode.*
FDA Label Image

Principal Display Panel (7.5 mcg Pouch Label)

Principal Display Panel (7.5 mcg Pouch Label)
Label for Butrans 7.5 mcg/hour buprenorphine transdermal system patch. The label specifies systemic delivery of 7.5 mcg/hour of buprenorphine over seven days. It includes warnings about serious breathing problems and usage instructions, highlighting the 7.5 mcg/hour dosage strength. The labeler is Knoa Pharma LLC, and the manufacturer is LTS Lohmann Therapy Systems Corp.*
FDA Label Image

Principal Display Panel (7.5 mcg Pouch Carton)

Principal Display Panel (7.5 mcg Pouch Carton)
Butrans 7.5 mcg/hour (buprenorphine) Transdermal System packaging label. The box design includes product name, strength, dosage form as a transdermal system, and warnings about patient use. It indicates the package contains 4 transdermal systems with disposal units, and it is labeled for opioid-experienced patients only. The labeler is Knoa Pharma LLC. The NDC is 59011-757-04.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.